VBI Vaccines Inc. (TSE:VBV – Get Free Report) shares fell 5.1% during mid-day trading on Monday . The company traded as low as C$4.82 and last traded at C$4.82. 1,300 shares were traded during trading, a decline of 64% from the average session volume of 3,637 shares. The stock had previously closed at C$5.08.
VBI Vaccines Stock Performance
The company has a debt-to-equity ratio of 14.29, a quick ratio of 2.54 and a current ratio of 2.64. The firm has a market capitalization of C$308.86 million and a PE ratio of -4.97.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Featured Stories
- Five stocks we like better than VBI Vaccines
- The How and Why of Investing in Gold Stocks
- The 3 Hottest Insiders Buys This Month
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- Short Selling: How to Short a Stock
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.